CN1065876C - Coded protein specific antibody having cytoskeleton gene - Google Patents
Coded protein specific antibody having cytoskeleton gene Download PDFInfo
- Publication number
- CN1065876C CN1065876C CN98111422A CN98111422A CN1065876C CN 1065876 C CN1065876 C CN 1065876C CN 98111422 A CN98111422 A CN 98111422A CN 98111422 A CN98111422 A CN 98111422A CN 1065876 C CN1065876 C CN 1065876C
- Authority
- CN
- China
- Prior art keywords
- gene
- jwa
- cells
- protein
- cytoskeleton
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 title claims description 20
- 210000004292 cytoskeleton Anatomy 0.000 title description 4
- 108700026244 Open Reading Frames Proteins 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 230000001900 immune effect Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 12
- 229920001184 polypeptide Polymers 0.000 abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 6
- 239000002299 complementary DNA Substances 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- WFDXOXNFNRHQEC-GHRIWEEISA-N azoxystrobin Chemical compound CO\C=C(\C(=O)OC)C1=CC=CC=C1OC1=CC(OC=2C(=CC=CC=2)C#N)=NC=N1 WFDXOXNFNRHQEC-GHRIWEEISA-N 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 19
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 10
- 238000011160 research Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 229960001338 colchicine Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229950006344 nocodazole Drugs 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- -1 Retinoid acids Chemical class 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
本发明属于人类基因组技术领域,所述细胞骨架样基因(JWA)全长cDNA序列为2107bp,其开放读框序列为564bp,共编码188个氨基酸。该基因在基因库(GenBank)编号为“BankIt 200994,Accession Number:AF070523”。本发明利用188个氨基酸中的部分序列合成多肽免疫动物制备多克隆和单克隆抗体。The invention belongs to the field of human genome technology. The full-length cDNA sequence of the cytoskeleton-like gene (JWA) is 2107bp, its open reading frame sequence is 564bp, and encodes 188 amino acids in total. The gene number in GenBank is "BankIt 200994, Accession Number: AF070523". The invention utilizes partial sequences of 188 amino acids to synthesize polypeptides to immunize animals to prepare polyclonal and monoclonal antibodies.
Description
本发明属于人类基因组技术领域。The invention belongs to the technical field of human genome.
本发明所述细胞骨架样基因(JWA)是发明人在美国加州大学戴维斯(UCDavis)访问研究期间(1996.3~1998.3)用DD-PCR,噬菌体筛选法,RACE-PCR等方法从人气管支气管上皮细胞构建的cDNA文库中克隆的与细胞骨架有关的全新基因。该基因全长cDNA序列为2107bp,其开放读框序列为564bp,共编码188个氨基酸。进一步研究显示JWA基因开放读框序列中含有三个膜转运区,每个区含有23个氨基酸,在三个膜转运区的两端有蛋白激酶C(PKC)磷酸化位点。Northern杂交分析显示该基因有两个大小不同的mRNA转录物,经反向转录,3′-RACE-PCR,Southern杂交分析和Rnase Protection Assay等研究已确定两个转录物的确切终止位置。用携带JWA基因开放读框序列的表达载体(PCMV-2-Flag-JWA)转染S-6和HBE细胞后的免疫荧光染色结果显示JWA基因编码的蛋白酷似细胞骨架微管。该蛋白明显地受去聚合剂colchicine和nocodazole的影响但不受冷处理的影响。另外,该基因在几种肿瘤细胞中的表达明显地受去甲基化药物5-azacytidin的影响。The cytoskeleton-like gene (JWA) of the present invention was obtained by using DD-PCR, phage screening method, RACE-PCR and other methods during the research period (1996.3~1998.3) of the inventor at the University of California, Davis (UCDavis). A novel gene related to the cytoskeleton cloned from a cDNA library constructed from human tracheal bronchial epithelial cells. The full-length cDNA sequence of the gene is 2107bp, and its open reading frame sequence is 564bp, encoding a total of 188 amino acids. Further studies showed that the open reading frame sequence of JWA gene contains three membrane translocation regions, each region contains 23 amino acids, and there are protein kinase C (PKC) phosphorylation sites at both ends of the three membrane translocation regions. Northern hybridization analysis showed that the gene had two mRNA transcripts of different sizes, and the exact termination positions of the two transcripts had been determined by reverse transcription, 3′-RACE-PCR, Southern hybridization analysis and Rnase Protection Assay. The results of immunofluorescence staining after transfection of S-6 and HBE cells with the expression vector carrying the open reading frame sequence of JWA gene (PCMV-2-Flag-JWA) showed that the protein encoded by JWA gene resembled cytoskeleton microtubules. The protein was clearly affected by the depolymerizing agents colchicine and nocodazole but not by cold treatment. In addition, the expression of this gene in several tumor cells was significantly affected by the demethylating drug 5-azacytidin.
由于JWA基因序列在GenBank数据库中尚无同源性基因,故发明人对于JWA基因的结构和功能研究结果全部是开创性的。美国国家生物技术情报中心(National Center for Biotechnology Information,NCBI)己于最近正式接受JWA基因作为GenBank的新成员。该基因编号为“BankIt 200994,Accession Number:AF070523”。GAATTCGGCACGAGCCGAGACGGAGCCGCTGTCAACTCTCCAACTCAGCTCAGCTGATCGGTTGCCGCCGCCGCCGCCGCCAGATTCTGGAGGCGAAGAACGCAAAGCTGAGAACATGGACGTTAATATCGCCCCACTCCGCGCCTGGGACGATTTCTTCCCGGGTTCCGATCGCTTTGCCCGGCCGGACTTCAGGGACATTTCCAAATGGAACAACCGCGTAGTGAGCAACCTGCTCTATTACCAGACCAACTACCTGGTGGTGGCTGCCATGATGATTTCCATTGTGGGGTTTCTGAGTCCCTTCAACATGATCCTGGGAGGAATCGTGGTGGTGCTGGTGTTCACAGGGTTTGTGTGGGCAGCCCACAATAAAGACGTCCTTCGCCGGATGAAGAAGCGCTACCCCACGACGTTCGTTATGGTGGTCATGTTGGCGAGCTATTTCCTTATCTCCATGTTTGGAGGAGTCATGGTCTTTGTGTTTGGCATTACTTTTCCTTTGCTGTTGATGTTTATCCATGCATCGTTGAGACTTCGGAACCTCAAGAACAAACTGGAGAATAAAATGGAAGGAATAGGTTTGAAGAGGACACCGATGGGCATTGTCCTGGATGCCCTAGAACAGCAGGAAGAAGGCATCAACAGACTCACTGACTATATCAGCAAAGTGAAGGAATAAACATAACTTACCTGAGCTAGGGTTGCAGCAGAAATTGAGTTGCAGCTTGCCCTTGTCCAGACCTATGTTCTGCTTGCGTTTTTGAAACAGGAGGTGCACGTACCACCCAATTATCTATGGCAGCATGCATGTATAGGCCGAACTATTATCAGCTCTGATGTTTCAGAGAGAAGACCTCAGAAACCGAAAGAAAACCACCACCCTCCTATTGTGTCTGAAGTTTCACGTGTGTTTATGAAATCTAATGGGAAATGGATCACACGATTTCTTTAAGGGAATTAAAAAAAATAAAAGAATTACGGCTTTTACAGCAACAATACGATTATCTTATAGGAAAAAAAAAAATCATTGTAAAGTATCAAGACAATACGAGTAAATGAAAAGGCTGTTAAAGTAGATGACATCATGTGTTAGCCTGTTCCTAAATCCCTAGAATTGTAATGTGTGGGATATAAATTAGTTTTTATTATTCTCTTAAAAATCAAAGATGATCTCTATCACTTTGCCACCTGTTTGATGTGCAGTGGAAACTGGTTAAGCCAGTTGTTCATACTTCCTTTACAAATATAAAGATAGCTGTTTAGGATATTTTGTTACATTTTTGTAAATTTTTGAAATGCTAGTAATGTGTTTTCACCAGCAAGTATTTGTTGCAAACTTAATGTCATTTTCCTTAAGATGGTTACAGCTATGTAACCTGTATTATTCTGGACGGACTTATTAAAATACAAACAGACAAAAAATAAAACAAAACTTGAGTTCTATTTACCTTGCACATTTTTTGTTGTTACAGTGAAAAAAATGGTCCAAGAAAATGTTTGCCATTTTTGCATTGTTTCGTTTTTAACTGGAACATTTAGAAAGAAGGAAATGAATGTGCATTTTATTAATTCCTTAGGGGCACAAGGAGGACAATAATAGCTGATCTTTTGAAATTTGAAAAACGTCTTTAGATGACCAAGCAAAAAGACTTTAAAAAATGGTAATGAAAATGGAATGCAGCTACTGCAGCTAATAAAAAATTTTAGATAGCAATTGTTACAACCATATGCCTTTATAGCTAGACATTAGAATTATGATAGCATGAGTTTATACATTCTATTATTTTTCCTCCCTTTCTCATGTTTTTATAAATAGGTAATAAAAAATGTTTTGCCTGCCAATTGAATGATTTCGTAGCTGAAGTAGAAACATTTAGGTTTCTGTAGCATTAAATTGTGAAGACAACTGGAGTGGTACTTACTGAAGAAACTCTCTGTATGTCCTAGAATAAGAAGCAATGATGTGCTGCTTCTGATTTTTCTTGCATTTTAAATTCTCAGCCAACCTACAGCCATGATCTTTAGCACAGTGATATCACCATGACTTCACAGACATGGTCTAGAATCTGTACCCTTACCCACATATGAAGAATAAAATTGATTAAAGGTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTCGAGJWA基因cDNA序列MDVNIAPLRAWDDFFPGSDRFARPDFRDISKWNNRVVSNLLYYQTNYLVV 50AAMMISIV(1)GFLSPFNMILGGIVVVLVFTGFVWAAHN(2)KDVLRRMKKRYPTT 100FVMVVMLASYFLISMFGGVMVFVFGITFPL(3)LLMFIHASLRLRNLKNKLEN 150KMEGIGLKRTPMGIVLDALEQQEEGINRLTDYISKVKE 188Since there is no homologous gene in the JWA gene sequence in the GenBank database, the inventors' research results on the structure and function of the JWA gene are all groundbreaking. The National Center for Biotechnology Information (NCBI) has recently officially accepted JWA gene as a new member of GenBank. The gene number is "BankIt 200994, Accession Number: AF070523". GAATTCGGCACGAGCCGAGACGGAGCCGCTGTCAACTCTCCAACTCAGCTCAGCTGATCGGTTGCCGCCGCCGCCGCCGCCAGATTCTGGAGGCGAAGAACGCAAAGCTGAGAACATGGACGTTAATATCGCCCCACTCCGCGCCTGGGACGATTTCTTCCCGGGTTCCGATCGCTTTGCCCGGCCGGACTTCAGGGACATTTCCAAATGGAACAACCGCGTAGTGAGCAACCTGCTCTATTACCAGACCAACTACCTGGTGGTGGCTGCCATGATGATTTCCATTGTGGGGTTTCTGAGTCCCTTCAACATGATCCTGGGAGGAATCGTGGTGGTGCTGGTGTTCACAGGGTTTGTGTGGGCAGCCCACAATAAAGACGTCCTTCGCCGGATGAAGAAGCGCTACCCCACGACGTTCGTTATGGTGGTCATGTTGGCGAGCTATTTCCTTATCTCCATGTTTGGAGGAGTCATGGTCTTTGTGTTTGGCATTACTTTTCCTTTGCTGTTGATGTTTATCCATGCATCGTTGAGACTTCGGAACCTCAAGAACAAACTGGAGAATAAAATGGAAGGAATAGGTTTGAAGAGGACACCGATGGGCATTGTCCTGGATGCCCTAGAACAGCAGGAAGAAGGCATCAACAGACTCACTGACTATATCAGCAAAGTGAAGGAATAAACATAACTTACCTGAGCTAGGGTTGCAGCAGAAATTGAGTTGCAGCTTGCCCTTGTCCAGACCTATGTTCTGCTTGCGTTTTTGAAACAGGAGGTGCACGTACCACCCAATTATCTATGGCAGCATGCATGTATAGGCCGAACTATTATCAGCTCTGATGTTTCAGAGAGAAGACCTCAGAAACCGAAAGAAAACCACCACCCTCCTATTGTGTCTGAAGTTTCACGTGTGTTTATGAAATCTAATGGGAAATGGATCACACGATTTCTTTAAGGGAATTAAAAAAAATAAAAGAATTACGGCTTTTACAGCAACAATACGATTATCTTATAGGAAAAAAAAAAATCATTGTAAAGTATCAAGACAATACGAGTAAATGAAAAGGCTGTTAAAGTAGATGACATCATGTGTTAGCCTGTTCCTAAATCCCTAGAATTGTAATGTGTGGGATATAAATTAGTTTTTATTATTCTCTTAAAAATCAAAGATGATCTCTATCACTTTGCCACCTGTTTGATGTGCAGTGGAAACTGGTTAAGCCAGTTGTTCATACTTCCTTTACAAATATAAAGATAGCTGTTTAGGATATTTTGTTACATTTTTGTAAATTTTTGAAATGCTAGTAATGTGTTTTCACCAGCAAGTATTTGTTGCAAACTTAATGTCATTTTCCTTAAGATGGTTACAGCTATGTAACCTGTATTATTCTGGACGGACTTATTAAAATACAAACAGACAAAAAATAAAACAAAACTTGAGTTCTATTTACCTTGCACATTTTTTGTTGTTACAGTGAAAAAAATGGTCCAAGAAAATGTTTGCCATTTTTGCATTGTTTCGTTTTTAACTGGAACATTTAGAAAGAAGGAAATGAATGTGCATTTTATTAATTCCTTAGGGGCACAAGGAGGACAATAATAGCTGATCTTTTGAAATTTGAAAAACGTCTTTAGATGACCAAGCAAAAAGACTTTAAAAAATGGTAATGAAAATGGAATGCAGCTACTGCAGCTAATAAAAAATTTTAGATAGCAATTGTTACAACCATATGCCTTTATAGCTAGACATTAGAATTATGATAGCATGAGTTTATACATTCTATTATTTTTCCTCCCTTTCTCATGTTTTTATAAATAGGTAATAAAAAATGTTTTGCCTGCCAATTGAATGATTTCGTAGCTGAAGTAGAAACATTTAGGTTTCTGTAGCATTAAATTGTGAAGACAACTGGAGTGGTACTTACTGAAGAAACTCTCTGTATGTCCTAGAATAAGAAGCAATGATGTGCTGCTTCTGATTTTTCTTGCATTTTAAATTCTCAGCCAACCTACAGCCATGATCTTTAGCACAGTGATATCACCATGACTTCACAGACATGGTCTAGAATCTGTACCCTTACCCACATATGAAGAATAAAATTGATTAAAGGTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTCGAGJWA基因cDNA序列MDVNIAPLRAWDDFFPGSDRFARPDFRDISKWNNRVVSNLLYYQTNYLVV 50AAMMISIV(1)GFLSPFNMILGGIVVVLVFTGFVWAAHN(2)KDVLRRMKKRYPTT 100FVMVVMLASYFLISMFGGVMVFVFGITFPL(3)LLMFIHASLRLRNLKNKLEN 150KMEGIGLKRTPMGIVLDALEQQEEGINRLTDYISKVKE 188
JWA基因开放读框氨基酸序列Amino acid sequence of open reading frame of JWA gene
序列中(1),(2),(3)为三个膜转运区,SDR和SLR为PKC磷酸化位点In the sequence (1), (2), (3) are three membrane translocation regions, SDR and SLR are PKC phosphorylation sites
本发明的目的是:鉴于JWA基因是本发明人发现的全新基因,目前人类对此基因的认识和了解仅限于本发明人所做的科学研究工作。本发明人用NorthernBlot,Western Blot,基因转染和荧光免疫组织化学染色等方法研究证实,JWA基因表达一种新的细胞骨架蛋白。该基因广泛存在于所研究的多种组织和细胞,其mRNA的表达受诱导分化剂维甲酸(Retinoid acids),氧化剂过氧化氢(H2O2),去甲基化药物(5-Azacytidin)等的明显影响;该基因编码蛋白的表达明显地受去聚合剂秋水仙素(Colchicine)和Nocodazole的影响以及热休克处理等的影响。JWA基因的进化保守,表达活跃的特征提示该基因具有十分活跃的生物学功能。尤其是其作为一种新的细胞骨架蛋白,对细胞的增殖和分化都有非常重要的作用。进一步研究JWA基因编码蛋白在细胞内的确切定位,有助于对该基因生物学功能的了解。而基因编码蛋白特异性抗体则是研究基因结构和功能的不可缺少的重要工具。JWA基因编码蛋白多克隆和单克隆特异性抗体,可用作免疫组织化学染色,ELISA,免疫电镜,免疫沉淀等多种根据免疫学原理设计的检测方法。可用于该基因编码蛋白在组织细胞中的定位和定量研究,在各种生物样本(如血液,尿液等)中的含量变化研究以及蛋白质-蛋白质相互作用研究等。The purpose of the present invention is: in view of the fact that the JWA gene is a brand-new gene discovered by the inventor, the current human knowledge and understanding of this gene is limited to the scientific research work done by the inventor. The present inventors use methods such as Northern Blot, Western Blot, gene transfection and fluorescent immunohistochemical staining to confirm that JWA gene expresses a new cytoskeleton protein. This gene widely exists in various tissues and cells studied, and its mRNA expression is significantly affected by the differentiation-inducing agent retinoic acid (Retinoid acids), the oxidizing agent hydrogen peroxide (H2O2), and the demethylation drug (5-Azacytidin). Influence; the expression of the encoded protein of this gene is obviously affected by the depolymerization agent colchicine (Colchicine) and Nocodazole and heat shock treatment. The evolutionary conservation of the JWA gene and its active expression suggest that the gene has very active biological functions. Especially as a new cytoskeleton protein, it plays a very important role in cell proliferation and differentiation. Further research on the exact location of the protein encoded by the JWA gene in cells will help to understand the biological function of the gene. Gene-encoded protein-specific antibodies are an indispensable and important tool for studying gene structure and function. JWA gene encodes protein polyclonal and monoclonal specific antibodies, which can be used as immunohistochemical staining, ELISA, immunoelectron microscopy, immunoprecipitation and other detection methods designed according to immunological principles. It can be used for the localization and quantitative research of the protein encoded by the gene in tissue cells, the research of content changes in various biological samples (such as blood, urine, etc.), and the research of protein-protein interaction.
本发明的技术方案是:JWA基因全部开放读框氨基酸序列(共188个氨基酸,见本申请所列),特别是含有亲水氨基酸区的C末端15个氨基酸,N末端30个氨基酸,第80~100个氨基酸和第135~155个氨基酸序列。选择上述序列中的部分序列合成多肽,与KLH载体蛋白结合后,用完全和不完全佐剂混合,免疫新西兰兔(200ug/兔/次,每周激发注射一次),制备多克隆抗体(anti-JWA IgG);免疫Balb C鼠(100ug/鼠/次,每月激发注射一次),分离脾脏B淋巴细胞并和骨髓瘤细胞融合产生杂交瘤细胞,进一步用亚克隆方法,ELISA法和抗体分型方法筛选分泌IgG抗体的单克隆,制备单克隆抗体(anti-JWA IgG)。The technical solution of the present invention is: the amino acid sequence of the entire open reading frame of the JWA gene (a total of 188 amino acids, as listed in this application), especially the C-terminal 15 amino acids containing the hydrophilic amino acid region, the N-terminal 30 amino acids, and the 80th amino acid sequence. ~100 amino acids and amino acid sequences 135-155. Select a partial sequence of the above sequence to synthesize a polypeptide, combine with KLH carrier protein, mix with complete and incomplete adjuvant, immunize New Zealand rabbits (200ug/rabbit/time, stimulate injection once a week), and prepare polyclonal antibody (anti- JWA IgG); immunize Balb C mice (100ug/mouse/time, challenge injection once a month), separate spleen B lymphocytes and fuse with myeloma cells to generate hybridoma cells, and further use subcloning methods, ELISA methods and antibody typing Methods The monoclonal antibody secreting IgG was screened to prepare the monoclonal antibody (anti-JWA IgG).
本发明实施例:Embodiments of the invention:
1.细胞骨架样基因编码蛋白特异性多克隆抗体取合成的JWA基因编码氨基酸C末端15个氨基酸多肽(序列为:DALEQQEEGINRLTD,分子量:1731)10mg,与载体蛋白KLH(Keyhole LimpetHymocyanin)结合,经透析后再与完全/不完全佐剂(Complete/Incomplete Freund’sAdjuvant)混合,免疫新西兰兔(背部皮下注射),每隔3~4周激发注射一次,于三个月后取血分离血清。以免疫前动物血清作为对照做ELISA测定各免疫兔血清中抗体滴度。筛选高滴度血清,进一步用抗原作竞争抑制免疫试验确定抗原的特异性。根据ELISA结果确定其用于免疫组织化学染色的稀释倍增数为1∶200~500。1. Cytoskeleton-like gene-encoded protein-specific polyclonal antibody takes 10 mg of synthetic JWA gene-encoded amino acid C-terminal 15 amino acid polypeptide (sequence: DALEQQEEGINRLTD, molecular weight: 1731), combined with carrier protein KLH (Keyhole LimpetHymocyanin), and then dialyzed Mix with Complete/Incomplete Freund's Adjuvant, immunize New Zealand rabbits (subcutaneous injection on the back), challenge and inject once every 3 to 4 weeks, and collect blood to separate serum after three months. Antibody titers in each immunized rabbit serum were determined by ELISA with pre-immunized animal serum as a control. Screen high-titer sera, and further use the antigen as a competitive inhibition immunoassay to determine the specificity of the antigen. According to the results of ELISA, the dilution doublings for immunohistochemical staining were determined to be 1:200-500.
细胞骨架样基因编码蛋白特异性多克隆抗体用于western blot试验:(1).用1640培养液(含10%胎牛血清)培养CHL/SMMC7723细胞于60mm培养皿中至100%覆盖率(通常5~7天),然后用/不用1~3mM的H2O2/10(-6)M的维甲酸/5~l0ng/ml的5-Azacytin/10ng/ml的colchicine处理细胞3~24小时;(2).用PBS洗细胞3次,吸去PBS,用100ul2倍的SDS溶解和收集细胞,加入5%的β巯基乙醇,95℃加热10分钟,加入溴酚蓝后用14.5%的聚丙烯酰胺凝胶电泳分离蛋白(70V 30min),然后将蛋白转移到尼龙膜上。(3).用含5%脱脂奶粉和1/500正常羊血清的PBST先封闭尼龙膜(置摇床上30min)。然后加入1∶200的一抗(兔抗JWA IgG),室温1小时。(4).用PBST洗涤五次,每次五分钟。然后加入生物素标记的羊抗兔IgG(1∶1000),室温1小时。(5).用PBST洗涤五次,每次五分钟。加入ABC试剂,室温30分钟。(6).用PBST洗涤五次,每次五分钟。用DAB显色。比较不同组细胞JWA基因编码蛋白在不同处理条件下的变化。从而分析影响JWA蛋白表达因素。Cytoskeleton-like gene-encoded protein-specific polyclonal antibody was used in western blot test: (1). Culture CHL/SMMC7723 cells in 1640 culture medium (containing 10% fetal bovine serum) in 60mm culture dishes to 100% coverage (usually 5-7 days), and then use/not use 1-3mM H 2 O 2 /10( -6) M retinoic acid/5-l0ng/ml 5-Azacytin/10ng/ml colchicine treated cells for 3-24 hours; (2). Wash the cells with PBS for 3 times, suck off the PBS, dissolve and collect the cells with 100ul of 2 times SDS, add 5% β-mercaptoethanol, heat at 95°C for 10 minutes, add bromophenol blue, gel with 14.5% polyacrylamide The protein was separated by gel electrophoresis (70V 30min), and then the protein was transferred to a nylon membrane. (3). The nylon membrane was first blocked with PBST containing 5% skimmed milk powder and 1/500 normal sheep serum (on a shaker for 30 min). Then a 1:200 primary antibody (rabbit anti-JWA IgG) was added for 1 hour at room temperature. (4). Wash five times with PBST for five minutes each. Then biotin-labeled goat anti-rabbit IgG (1:1000) was added for 1 hour at room temperature. (5). Wash five times with PBST for five minutes each. Add ABC reagent, room temperature for 30 minutes. (6). Wash five times with PBST for five minutes each. Color was developed with DAB. Compare the changes of JWA gene encoded protein in different groups of cells under different treatment conditions. In order to analyze the factors affecting the expression of JWA protein.
2.细胞骨架样基因编码蛋白特异性单克隆抗体取合成的JWA基因编码氨基酸C末端15个氨基酸多肽(序列为:DALEQQEEGINRLTD,分子量:1731)10mg,与载体蛋白KLH(Keyhole LimpetHymocyanin)结合,经透析后再与完全/不完全佐剂(Complete/Incomplete Freund’sAdjuvant)混合,免疫Balb/C小鼠(腹部皮下注射),每月激发注射一次,连续免疫四个月后取血分离血清,取脾脏分离B淋巴细胞,然后与骨髓瘤细胞融合产生杂交瘤细胞。经多次亚克隆和用抗原(合成多肽)及IgG筛选获得分泌抗JWA合成多肽IgG的杂交瘤细胞株。用ELISA确定抗体的滴度。2. Cytoskeleton-like gene-encoded protein-specific monoclonal antibody takes 10 mg of synthetic JWA gene-encoded amino acid C-terminal 15 amino acid polypeptide (sequence: DALEQQEEGINRLTD, molecular weight: 1731), combined with carrier protein KLH (Keyhole LimpetHymocyanin), and then dialyzed Mix with Complete/Incomplete Freund's Adjuvant, immunize Balb/C mice (abdominal subcutaneous injection), challenge injection once a month, after four months of continuous immunization, take blood to separate serum, and take spleen to separate B The lymphocytes are then fused with myeloma cells to produce hybridoma cells. A hybridoma cell line secreting anti-JWA synthetic polypeptide IgG was obtained through multiple subcloning and screening with antigen (synthetic polypeptide) and IgG. Antibody titers were determined by ELISA.
细胞骨架样基因编码蛋白特异性单克隆抗体用于培养细胞的荧光免疫组织化学染色试验:(1).用1640培养液(含10%胎牛血清)培养CHL/SMMC7723细胞于35mm培养皿中至100%覆盖率(通常5~7天),然后用/不用1~3mm的H2O2/10(-6)M的维甲酸/5~10ng/ml的5-Azacytin/10ng /ml的colchicine处理细胞3~24小时;用甲醇固定细胞10min。(2)用PBS洗涤细胞2~3次,加入1∶500的正常羊血清封闭30min。再用PBS洗涤细胞2~3次后加入1∶1000的鼠抗JWA基因编码蛋白单克隆抗体,37℃温育1小时。(3).用PBS洗涤细胞5次,加入1∶200的荧光素标记的羊抗鼠IgG37℃温育1小时。(4)用PBS洗涤细胞5次,制片后用荧光显微镜观察JWA基因蛋白在细胞内的分布特征。Cytoskeleton-like gene-encoded protein-specific monoclonal antibody used in fluorescent immunohistochemical staining test of cultured cells: (1). Cultivate CHL/SMMC7723 cells in 1640 culture medium (containing 10% fetal bovine serum) to 100% coverage (usually 5-7 days) in a 35mm culture dish, and then use/not use 1-3mm of H 2 O 2 /10( -6) Treat the cells with M retinoic acid/5-10 ng/ml 5-Azacytin/10 ng/ml colchicine for 3-24 hours; fix the cells with methanol for 10 minutes. (2) Wash the cells 2-3 times with PBS, add 1:500 normal goat serum to block for 30 min. Then wash the cells with PBS for 2-3 times, add 1:1000 mouse anti-JWA gene-encoded protein monoclonal antibody, and incubate at 37°C for 1 hour. (3). Wash the cells 5 times with PBS, add 1:200 fluorescein-labeled goat anti-mouse IgG and incubate at 37°C for 1 hour. (4) The cells were washed 5 times with PBS, and the distribution characteristics of the JWA gene protein in the cells were observed with a fluorescence microscope after preparation.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98111422A CN1065876C (en) | 1998-07-22 | 1998-07-22 | Coded protein specific antibody having cytoskeleton gene |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98111422A CN1065876C (en) | 1998-07-22 | 1998-07-22 | Coded protein specific antibody having cytoskeleton gene |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1208733A CN1208733A (en) | 1999-02-24 |
CN1065876C true CN1065876C (en) | 2001-05-16 |
Family
ID=5221403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98111422A Expired - Fee Related CN1065876C (en) | 1998-07-22 | 1998-07-22 | Coded protein specific antibody having cytoskeleton gene |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1065876C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021027045A1 (en) | 2019-08-12 | 2021-02-18 | 周建伟 | Anti-tumour compound based on jwa gene activation and her2 degradation, preparation method therefor, and use thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102297971A (en) * | 2011-06-15 | 2011-12-28 | 南京医科大学 | Kit for detecting expression of JWA in cancer or malignant tumor tissue |
CN103239710B (en) * | 2013-05-14 | 2014-09-24 | 南京医科大学 | Polypeptides with anti-tumor activity and uses thereof |
CN110201173B (en) * | 2019-06-21 | 2020-11-10 | 周建伟 | Anti-aging application of JWA gene and related compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1171133A (en) * | 1994-10-14 | 1998-01-21 | 大制药株式会社 | Gene participating in apoptosis |
CN1190437A (en) * | 1995-06-07 | 1998-08-12 | 吉恩赛再生科学公司 | Bone stimulating factor |
-
1998
- 1998-07-22 CN CN98111422A patent/CN1065876C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1171133A (en) * | 1994-10-14 | 1998-01-21 | 大制药株式会社 | Gene participating in apoptosis |
CN1190437A (en) * | 1995-06-07 | 1998-08-12 | 吉恩赛再生科学公司 | Bone stimulating factor |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021027045A1 (en) | 2019-08-12 | 2021-02-18 | 周建伟 | Anti-tumour compound based on jwa gene activation and her2 degradation, preparation method therefor, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1208733A (en) | 1999-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0344134B1 (en) | Monoclonal antibody specific to a fibronectin sequence expressed in transformed cells, hybridoma secreting said antibody and use of said monoclonal antibody in the diagnosis of tumors | |
EP0514481B1 (en) | Merosin, nucleic acids encoding, fragments and uses thereof | |
CN1065876C (en) | Coded protein specific antibody having cytoskeleton gene | |
JP4374316B2 (en) | Antibody to β-amyloid or a derivative thereof and use thereof | |
CN112812179A (en) | High-affinity high-specificity anti-CMTM 6 monoclonal antibody and application thereof | |
JP4201712B2 (en) | GIP, a family of polypeptides with transcription factor activity that interact with Goodpasture antigen binding proteins | |
JP2001122900A (en) | ANTI-DNASE gamma ANTIBODY AND ITS PREPARATION AND USE | |
EP0831148B1 (en) | Human adhesion molecule occludin | |
Salata et al. | Application of an immune-tolerizing procedure to generate monoclonal antibodies specific to an alternate protein isoform of bovine growth hormone | |
KR102052882B1 (en) | Use of STIM2 inhibitor for preventing or treating Brody syndrome or Brody disease | |
JP3894381B2 (en) | Anti-Glu ▲ 17 ▼ -osteocalcin antibody | |
US5541101A (en) | Anti-oxytocin receptor antibodies | |
US5624905A (en) | Merosin fragments and uses thereof | |
EP1367123A1 (en) | Neurotonin and use thereof | |
JP3472664B2 (en) | Anti-fibroblast growth factor 5 monoclonal antibody | |
JP2871743B2 (en) | Monoclonal antibodies and hybridomas secreting the antibodies | |
JPH06125784A (en) | Monoclonal antibody, hybridoma, its production and use | |
CN100381466C (en) | A kind of human Pif1 gene, its encoded protein and its application | |
JP3522877B2 (en) | Anti-tyrosinase monoclonal antibody F (ab ') 2 fragment | |
JPH02152988A (en) | Peptide compound and antiserum and antibody produced by using the peptide compound | |
WO2004101824A1 (en) | Method of detecting chronic obstructive pulmonary disease | |
JP2902129B2 (en) | Method for detecting basic fibroblast growth factor | |
CN118291393A (en) | PCLAF-NAb monoclonal antibody, hybridoma cell line, application | |
NZ268592A (en) | Mammamodulin, antibodies therefor, and pharmaceutical compositions, treatment of breast cancer | |
CN109957015A (en) | A kind of preparation method and applications of HMGB1 blocking antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20010516 Termination date: 20130722 |